NO20005621D0 - Nye medikamentkombinasjoner - Google Patents

Nye medikamentkombinasjoner

Info

Publication number
NO20005621D0
NO20005621D0 NO20005621A NO20005621A NO20005621D0 NO 20005621 D0 NO20005621 D0 NO 20005621D0 NO 20005621 A NO20005621 A NO 20005621A NO 20005621 A NO20005621 A NO 20005621A NO 20005621 D0 NO20005621 D0 NO 20005621D0
Authority
NO
Norway
Prior art keywords
disorders
new drug
drug combinations
anxiety
nari
Prior art date
Application number
NO20005621A
Other languages
English (en)
Other versions
NO20005621L (no
Inventor
Duncan Paul Taylor
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO20005621L publication Critical patent/NO20005621L/no
Publication of NO20005621D0 publication Critical patent/NO20005621D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20005621A 1998-05-08 2000-11-07 Nye medikamentkombinasjoner NO20005621D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8486098P 1998-05-08 1998-05-08
PCT/US1999/006523 WO1999058130A1 (en) 1998-05-08 1999-04-14 New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol

Publications (2)

Publication Number Publication Date
NO20005621L NO20005621L (no) 2000-11-07
NO20005621D0 true NO20005621D0 (no) 2000-11-07

Family

ID=22187677

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005621A NO20005621D0 (no) 1998-05-08 2000-11-07 Nye medikamentkombinasjoner

Country Status (22)

Country Link
EP (1) EP1075264B1 (no)
JP (1) JP2002514601A (no)
KR (1) KR20010052319A (no)
CN (1) CN1300217A (no)
AT (1) ATE283694T1 (no)
AU (1) AU764579B2 (no)
BR (1) BR9909559A (no)
CA (1) CA2326105A1 (no)
DE (1) DE69922367T2 (no)
EA (1) EA003469B1 (no)
ES (1) ES2232128T3 (no)
HU (1) HUP0101341A3 (no)
IL (1) IL139211A0 (no)
NO (1) NO20005621D0 (no)
NZ (1) NZ508035A (no)
PL (1) PL345351A1 (no)
PT (1) PT1075264E (no)
SI (1) SI1075264T1 (no)
SK (1) SK14502000A3 (no)
TR (1) TR200003262T2 (no)
WO (1) WO1999058130A1 (no)
ZA (1) ZA200005301B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1459751B1 (en) * 1999-07-01 2005-09-14 Pharmacia & Upjohn Company LLC (S,S)-reboxetine for treating migraine headaches
ES2246488T3 (es) * 1999-07-01 2006-02-16 PHARMACIA & UPJOHN COMPANY LLC Reboxetina para tratar la migraña.
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
EP1551393A4 (en) 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
NZ556779A (en) 2002-12-27 2008-12-24 Otsuka Pharma Co Ltd Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
US20120077818A1 (en) * 2009-05-13 2012-03-29 Sunovion Pharmaceuticals Inc. Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
WO1997006792A1 (en) * 1995-08-16 1997-02-27 Eli Lilly And Company Potentiation of serotonin response

Also Published As

Publication number Publication date
SI1075264T1 (en) 2005-06-30
BR9909559A (pt) 2000-12-19
NO20005621L (no) 2000-11-07
SK14502000A3 (sk) 2001-05-10
AU764579B2 (en) 2003-08-21
ZA200005301B (en) 2001-10-01
PT1075264E (pt) 2005-01-31
EA200001162A1 (ru) 2001-04-23
EP1075264B1 (en) 2004-12-01
WO1999058130A1 (en) 1999-11-18
DE69922367D1 (de) 2005-01-05
CN1300217A (zh) 2001-06-20
KR20010052319A (ko) 2001-06-25
DE69922367T2 (de) 2005-12-22
JP2002514601A (ja) 2002-05-21
CA2326105A1 (en) 1999-11-18
AU3546099A (en) 1999-11-29
ES2232128T3 (es) 2005-05-16
TR200003262T2 (tr) 2001-03-21
PL345351A1 (en) 2001-12-17
NZ508035A (en) 2004-02-27
ATE283694T1 (de) 2004-12-15
HUP0101341A3 (en) 2006-07-28
EA003469B1 (ru) 2003-06-26
IL139211A0 (en) 2001-11-25
EP1075264A1 (en) 2001-02-14
HUP0101341A2 (hu) 2001-08-28

Similar Documents

Publication Publication Date Title
CY1107924T1 (el) Παραγωγα φαινυλ-πιπεραζινης ως αναστολεις επαναπροσληψης σεροτονινης
DE60233655D1 (de) R und retinoid x rezeptorenmodulatoren
CL2010001292A1 (es) Compuestos derivados de 1h-benzo[d]azepina; composicion farmaceutica; utiles para el tratamiento de un trastorno seleccionado entre obesidad, hiperfagia, trastorno obsesivo compulsivo, depresion, ansiedad, abuso de sustancias, trastornos del sueño, sofocos y/o hipogonadismo (division de solicitud de patente de invencion no 375-2005).
EE200100441A (et) Monoamiinide taasomastamise inhibiitorid kesknärvisüsteemi haiguste raviks
CY1109238T1 (el) Δισκιο περιεχον σετιριζινη και ψευδοεφεδρινη
TR200401291T4 (tr) Depresyon, obsesif kompülsif bozukluk ve psikozda kullanılmak üzre bir serotonin reuptake inhibitörü ve bir atipik antipsikotik kombinasyonu
NO20053185D0 (no) Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse.
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
NO20070914L (no) Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander
SI1075264T1 (en) New drug combinations of reboxetine and pindolol
DK1626720T3 (da) 4-(2-Phenylsulfanyl-phenyl)-piperidinderivater som serotonin-genoptagelseshæmmer
ATE457309T1 (de) Modulatoren von peripheren 5-ht-rezeptoren
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
MY136367A (en) Treatment of cognitive failure
WO2002040006A3 (en) Treatment of anxiety disorders
NO20051215L (no) Katalysator for nedbryting av N2O i Ostwald-prosessen
NO20055206L (no) 4-(2-fenyloksyfenyl)-piperidin eller -1,2,3,6-tetrahydropyridinderivater som serotonin-reopptaksinhibitorer
DK1071418T3 (da) Nye behandlinger til nervelidelser
EA200870533A1 (ru) Производные 3-(1н-индол-3-ил)индан-1-иламина для лечения депрессии и тревожности
NO20061425L (no) Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin
ATE291920T1 (de) Verwendung von quetiapin für aufmerksamkeitsmangel-hyperaktivitätsstörungen oder verhaltensstörungen
MY141048A (en) Morpholine derivatives as norepinephrine reuptake inhibitors
PT1282414E (pt) Compostos derivados de felbamato para o tratamento da dor neuropatica
UA81472C2 (en) 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
DE50211837D1 (de) Xenogene oligo- oder/und polyribonukleotide als mittel zur behandlung von malignen tumoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application